These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 32892451

  • 1. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.
    Gandhi T, Lawler P, Foxton E, Chowdary P, Riddell A.
    Haemophilia; 2020 Nov; 26(6):e300-e307. PubMed ID: 32892451
    [Abstract] [Full Text] [Related]

  • 2. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW, Chen LS, Jayakodi D, Dunkley SM.
    Thromb Res; 2013 Nov; 132(6):735-41. PubMed ID: 24119613
    [Abstract] [Full Text] [Related]

  • 3. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels.
    Boylan B, Miller CH.
    Haemophilia; 2018 May; 24(3):487-491. PubMed ID: 29461004
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P, Moore GW, Platton S, Maloney JC, Palmer B, Bowles L, Pasi KJ, Rangarajan S, Hart DP.
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
    Batty P, Riddell A, Kitchen S, Sardo Infirri S, Walker I, Woods T, Jennings I, Hart DP.
    Haemophilia; 2021 May; 27(3):490-499. PubMed ID: 33650732
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY, Vuyyala S, Prunty J, Schmaier AH, Nayak L.
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
    Guy S, Bowyer AE, Shepherd MF, Maclean RM, Kitchen S.
    Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [Abstract] [Full Text] [Related]

  • 20. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.
    Mizrahi T, Doyon K, Dubé E, Bonnefoy A, Warner M, Cloutier S, Demers C, Castilloux JF, Rivard GE, St-Louis J.
    Haemophilia; 2019 Mar; 25(2):252-257. PubMed ID: 30694571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.